Even With A Change At The Top, Danaher Corporation Will Roll On

A change in the CEO, sluggish near-term trends, and a more competitive M&A market isn't likely to lead to big changes.

Apr 17, 2014 at 6:30PM

Multi-industry conglomerate Danaher (NYSE:DHR) definitely buried the lede this quarter, as news of the unexpected retirement of well-liked CEO H. Lawrence Culp next year overshadowed an otherwise "OK ... but not great" quarter. Losing a good CEO is also a risk for a company, but Danaher is a consummate example of a company that reloads instead of rebuilds. These shares are not particularly cheap and they rarely ever are, but an overreaction to this news could perhaps create a window of opportunity.

A decent start to the year
Danaher did basically as expected, but investors often seem to expect a little extra from this company. Revenue rose 5% as reported, with core revenue growth of 3.5%. Results were rather balanced across the businesses. Test & Measurement was the laggard with just 1% core growth, Industrial Tech rose 3%, Environmental and Life Sciences & Diagnostics rose 4%, and Dental rose 6%. Dental and Industrial Tech were the only units to come in higher than expected, with a minor 1% beat for IT and a 3% beat for Dental.

Profitability was just slightly below sell-side targets, but not to a truly meaningful extent. Gross margin improved 30bp from last year. Operating income rose 8% on a 9% increase in segment income, with all units showing growth. Dental led the way with 20% growth, IT and LSD were next at 12% and 10%, while Environmental rose 8% and TM rose 3%. Overall operating margin rose half a point and every unit saw margin expansion.

Diagnostics not fully back up to speed
Danaher has made a lot of progress with its Beckman diagnostics business, but this quarter would suggest that the work isn't over just yet. Danaher couldn't match the high single-digit growth of either Abbott or Roche, even though this looked like a pretty solid quarter for immunoassay and clinical chemistry across the group. Danaher has been gaining share on Siemens (NASDAQOTH:SIEGY), but the company is going to need to improve its automation and molecular diagnostics if it wants to close the gap with Abbott and Roche.

Still waiting on test, while motion remains weak
As investors in Agilent (NYSE:A) know all too well, test & measurement can be an erratic business. Danaher is a little more focused than Agilent and it leads in oscilloscopes and handheld equipment, but push-outs in communications and weakness in government/military weighed on results. Agilent continues to sound bullish about an eventual recovery in communications-related T&M spending, and that should lift demand for Danaher's instruments as well.

I was a little more surprised to see ongoing weakness in Danaher's motion business (part of IT). Automation-related orders at Rockwell, Siemens and other players had been showing some strength (up around 7%), but that doesn't seem to be helping Danaher yet. This business should improve as the year goes on, but in the meantime business like retail petroleum and product ID are doing reasonably well.

A changing of the guard, but probably not the approach
Analysts and investors were definitely surprised to learn of CEO Culp's plan to retire next year, with EVP Thomas Joyce taking the position. Culp has done a fine job as CEO of Danaher and while this looks like an unusually young age to retire (he'll be 52 at the time), he will have been in the job for around 14 years. As Danaher is often lauded for its bench strength, there are good reasons to expect a lot from Mr. Joyce in the years to follow.

It seems safe to count on this move driving speculation about Danaher's ongoing business plan. Some analysts have advocated a major change in the company's approach, breaking up into smaller businesses and eschewing the conglomerate approach. I doubt that will happen. Danaher may have missed out on some M&A opportunities (Life Technologies, JNJ's diagnostics business, and Ashland's water tech business), but an unwillingness to overpay for assets does not argue for a radical strategic shift.

With $8 billion in financial resources, Danaher can still make some M&A moves, though a big move during this CEO transition period may be less likely. I would like to see Danaher add to its diagnostics business (particularly MDx), but a larger move in life sciences like Agilent (after it spins off the test and measurement business) or a bigger deal in industrial automation could make sense.

The bottom line
Danaher's business does not change much from quarter to quarter and neither does my valuation. I'm still looking for long-term revenue growth around 5% and FCF growth around 6%, and the shares do appear priced for only a mid-single digit return at this price. I'd be very reluctant to sell Danaher if I held the shares, but there are cheaper names to choose from today in my opinion.

The greatest thing Warren Buffett ever said
Warren Buffett has made billions through his investing and he wants you to be able to invest like him. Through the years, Buffett has offered up investing tips to shareholders of Berkshire Hathaway. Now you can tap into the best of Warren Buffett's wisdom in a new special report from The Motley Fool. Click here now for a free copy of this invaluable report.

Stephen D. Simpson, CFA owns shares of Roche. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information